These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28576573)

  • 1. Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology.
    Gilbert SC; Warimwe GM
    Vaccine; 2017 Aug; 35(35 Pt A):4461-4464. PubMed ID: 28576573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenovirus-vectored Ebola vaccines.
    Gilbert SC
    Expert Rev Vaccines; 2015; 14(10):1347-57. PubMed ID: 26289977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine development for emerging virulent infectious diseases.
    Maslow JN
    Vaccine; 2017 Oct; 35(41):5437-5443. PubMed ID: 28216184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.
    Warimwe GM; Lorenzo G; Lopez-Gil E; Reyes-Sandoval A; Cottingham MG; Spencer AJ; Collins KA; Dicks MD; Milicic A; Lall A; Furze J; Turner AV; Hill AV; Brun A; Gilbert SC
    Virol J; 2013 Dec; 10():349. PubMed ID: 24304565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine.
    Zhou Y; Sullivan NJ
    Curr Opin Immunol; 2015 Aug; 35():131-6. PubMed ID: 26247875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rethinking the Response to Emerging Microbes: Vaccines and Therapeutics in the Ebola Era--a Conference at Harvard Medical School.
    Knipe DM; Whelan SP
    J Virol; 2015 Aug; 89(15):7446-8. PubMed ID: 25995250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens.
    Fathi A; Dahlke C; Addo MM
    Hum Vaccin Immunother; 2019; 15(10):2269-2285. PubMed ID: 31368826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates.
    Terasaki K; Tercero BR; Makino S
    Virus Res; 2016 May; 216():55-65. PubMed ID: 26022573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.
    Ikegami T
    Expert Rev Vaccines; 2017 Jun; 16(6):601-611. PubMed ID: 28425834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.
    Suschak JJ; Schmaljohn CS
    Hum Vaccin Immunother; 2019; 15(10):2359-2377. PubMed ID: 31589088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CEPI: Driving Progress Toward Epidemic Preparedness and Response.
    Gouglas D; Christodoulou M; Plotkin SA; Hatchett R
    Epidemiol Rev; 2019 Jan; 41(1):28-33. PubMed ID: 31673694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global research trends of World Health Organization's top eight emerging pathogens.
    Sweileh WM
    Global Health; 2017 Feb; 13(1):9. PubMed ID: 28179007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus.
    Maslow JN
    Hum Vaccin Immunother; 2017 Dec; 13(12):2918-2930. PubMed ID: 28846484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One Health approach to Rift Valley fever vaccine development.
    Kortekaas J
    Antiviral Res; 2014 Jun; 106():24-32. PubMed ID: 24681125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates.
    Smith DR; Johnston SC; Piper A; Botto M; Donnelly G; Shamblin J; Albariño CG; Hensley LE; Schmaljohn C; Nichol ST; Bird BH
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006474. PubMed ID: 29742102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards a vaccine against Ebola virus.
    Geisbert TW; Jahrling PB
    Expert Rev Vaccines; 2003 Dec; 2(6):777-89. PubMed ID: 14711361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INFECTIOUS DISEASE. Camel vaccine offers hope to stop MERS.
    Kupferschmidt K
    Science; 2015 Dec; 350(6267):1453. PubMed ID: 26680169
    [No Abstract]   [Full Text] [Related]  

  • 18. Virology. New vaccine and treatment excite Ebola researchers.
    Enserink M
    Science; 2003 Nov; 302(5648):1141-2. PubMed ID: 14615510
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccination of alpacas against Rift Valley fever virus: Safety, immunogenicity and pathogenicity of MP-12 vaccine.
    Rissmann M; Ulrich R; Schröder C; Hammerschmidt B; Hanke D; Mroz C; Groschup MH; Eiden M
    Vaccine; 2017 Jan; 35(4):655-662. PubMed ID: 28012779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs.
    Busquets N; Lorenzo G; López-Gil E; Rivas R; Solanes D; Galindo-Cardiel I; Abad FX; Rodríguez F; Bensaid A; Warimwe G; Gilbert SC; Domingo M; Brun A
    Antiviral Res; 2014 Aug; 108():165-72. PubMed ID: 24933081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.